Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: Key findings at enrolment until 2017.

van Dorland HA, Mansouri Taleghani M, Sakai K, Friedman KD, George JN, Hrachovinova I, Knöbl PN, von Krogh AS, Schneppenheim R, Aebi-Huber I, Bütikofer L, Largiadèr CR, Cermakova Z, Kokame K, Miyata T, Yagi H, Terrell DR, Vesely SK, Matsumoto M, Lämmle B, Fujimura Y, Kremer Hovinga JA; Hereditary TTP Registry.

Haematologica. 2019 Feb 21. pii: haematol.2019.216796. doi: 10.3324/haematol.2019.216796. [Epub ahead of print]

2.

Performance of a recombinant fusion protein linking coagulation factor IX with recombinant albumin in one-stage clotting assays.

Horn C, Négrier C, Kalina U, Seifert W, Friedman KD.

J Thromb Haemost. 2019 Jan;17(1):138-148. doi: 10.1111/jth.14332. Epub 2018 Dec 16.

PMID:
30418692
3.

Von Willebrand disease in the United States: perspective from the Zimmerman program.

Flood VH, Abshire TC, Christopherson PA, Friedman KD, Cox Gill J, Montgomery RR, Haberichter SL; Zimmerman Program Investigators.

Ann Blood. 2018 Jan;3. pii: 7. doi: 10.21037/aob.2017.12.05. Epub 2018 Jan 26.

4.

Common VWF sequence variants associated with higher VWF and FVIII are less frequent in subjects diagnosed with type 1 VWD.

Flood VH, Johnsen JM, Kochelek C, Slobodianuk TL, Christopherson PA, Haberichter SL, Udani R, Bellissimo DB, Friedman KD, Montgomery RR.

Res Pract Thromb Haemost. 2018 Jan 23;2(2):390-398. doi: 10.1002/rth2.12077. eCollection 2018 Apr.

5.

Response: The coagulation laboratory monitoring of AFSTYLA single-chain FVIII concentrate.

Friedman KD, Powell JS, Bensen-Kennedy D.

Haemophilia. 2018 May;24(3):e129-e131. doi: 10.1111/hae.13450. Epub 2018 Mar 30. No abstract available.

PMID:
29603512
6.

International comparative field study evaluating the assay performance of AFSTYLA in plasma samples at clinical hemostasis laboratories.

St Ledger K, Feussner A, Kalina U, Horn C, Metzner HJ, Bensen-Kennedy D, Blackman N, Veldman A, Stowers A, Friedman KD.

J Thromb Haemost. 2018 Mar;16(3):555-564. doi: 10.1111/jth.13932. Epub 2018 Feb 1.

PMID:
29274194
7.

Successful kidney transplantation in a patient with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).

Fattah H, Kumar D, George JN, Massey HD, King AL, Friedman KD, Gupta G.

Transfusion. 2017 Dec;57(12):3058-3062. doi: 10.1111/trf.14326. Epub 2017 Sep 20.

PMID:
28940540
8.

Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy.

Epperla N, Hemauer K, Hamadani M, Friedman KD, Kreuziger LB.

Transfusion. 2017 Nov;57(11):2775-2781. doi: 10.1111/trf.14263. Epub 2017 Aug 23.

PMID:
28836275
9.

Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.

Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lämmle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H; International Working Group for Thrombotic Thrombocytopenic Purpura.

J Thromb Haemost. 2017 Feb;15(2):312-322. doi: 10.1111/jth.13571. Epub 2017 Jan 30.

10.

Differentiation of pernicious anemia from thrombotic thrombocytopenic purpura: The clinical value of subtle pathologic findings.

Abbott DW, Friedman KD, Karafin MS.

Transfus Apher Sci. 2016 Dec;55(3):318-322. doi: 10.1016/j.transci.2016.08.005. Epub 2016 Sep 28.

PMID:
27765664
11.

Effect of systemic bevacizumab in severe hereditary hemorrhagic telangiectasia associated with bleeding.

Epperla N, Kapke JT, Karafin M, Friedman KD, Foy P.

Am J Hematol. 2016 Jun;91(6):E313-4. doi: 10.1002/ajh.24367. Epub 2016 Apr 28. No abstract available.

12.

Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.

Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, Udani RA, Dasgupta M, Hoffmann RG, Ragni MV, Shapiro AD, Lusher JM, Lentz SR, Abshire TC, Leissinger C, Hoots WK, Manco-Johnson MJ, Gruppo RA, Boggio LN, Montgomery KT, Goodeve AC, James PD, Lillicrap D, Peake IR, Montgomery RR.

Blood. 2016 May 19;127(20):2481-8. doi: 10.1182/blood-2015-10-673681. Epub 2016 Feb 9.

13.

Congenital thrombotic thrombocytopenic purpura related to a novel mutation in ADAMTS13 gene and management during pregnancy.

Epperla N, Hemauer K, Friedman KD, George JN, Foy P.

Am J Hematol. 2016 Jun;91(6):644-6. doi: 10.1002/ajh.24311. No abstract available.

14.

A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.

Kitchen S, Blakemore J, Friedman KD, Hart DP, Ko RH, Perry D, Platton S, Tan-Castillo D, Young G, Luddington RJ.

J Thromb Haemost. 2016 Apr;14(4):757-64. doi: 10.1111/jth.13253. Epub 2016 Feb 18.

15.

A critical appraisal of one-stage and chromogenic assays of factor VIII activity.

Peyvandi F, Oldenburg J, Friedman KD.

J Thromb Haemost. 2016 Feb;14(2):248-61. doi: 10.1111/jth.13215. Epub 2016 Feb 1. Review.

16.

Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a new modified automated method.

Hillarp A, Friedman KD, Adcock-Funk D, Tiefenbacher S, Nichols WL, Chen D, Stadler M, Schwartz BA.

Haemophilia. 2015 Nov;21(6):837-45. doi: 10.1111/hae.12703. Epub 2015 Jul 14.

PMID:
26172561
17.

Crucial role for the VWF A1 domain in binding to type IV collagen.

Flood VH, Schlauderaff AC, Haberichter SL, Slobodianuk TL, Jacobi PM, Bellissimo DB, Christopherson PA, Friedman KD, Gill JC, Hoffmann RG, Montgomery RR; Zimmerman Program Investigators.

Blood. 2015 Apr 2;125(14):2297-304. doi: 10.1182/blood-2014-11-610824. Epub 2015 Feb 6.

18.

Allosteric activation of ADAMTS13 by von Willebrand factor.

Muia J, Zhu J, Gupta G, Haberichter SL, Friedman KD, Feys HB, Deforche L, Vanhoorelbeke K, Westfield LA, Roth R, Tolia NH, Heuser JE, Sadler JE.

Proc Natl Acad Sci U S A. 2014 Dec 30;111(52):18584-9. doi: 10.1073/pnas.1413282112. Epub 2014 Dec 15.

19.

Comparison of anti-Xa and dilute Russell viper venom time assays in quantifying drug levels in patients on therapeutic doses of rivaroxaban.

Gosselin RC, Adcock Funk DM, Taylor JM, Francart SJ, Hawes EM, Friedman KD, Moll S.

Arch Pathol Lab Med. 2014 Dec;138(12):1680-4. doi: 10.5858/arpa.2013-0750-OA.

PMID:
25427046
20.

Acquired von Willebrand syndrome in a child following Berlin Heart EXCOR Pediatric Ventricular Assist Device implantation: case report and concise literature review.

Costello JP, Diab YA, Philippe-Auguste M, Jones MB, Shankar V, Friedman KD, Nath DS.

World J Pediatr Congenit Heart Surg. 2014 Oct;5(4):592-8. doi: 10.1177/2150135114539521. Review.

PMID:
25324261
21.

Life-threatening bleeding in a patient with mild hemophilia A and heterozygosity for von Willebrand disease Type 2N.

Allan JN, Friedman KD, DeSancho MT.

Int J Hematol. 2014 Dec;100(6):602-6. doi: 10.1007/s12185-014-1662-3. Epub 2014 Sep 12.

PMID:
25212677
22.

Diagnostic challenges in patients with bleeding phenotype and von Willebrand exon 28 polymorphism p.D1472H.

Francis JC, Hui SK, Mahoney D Jr, Dietrich JE, Friedman KD, Soundar E, Srivaths LV.

Haemophilia. 2014 May;20(3):e211-4. doi: 10.1111/hae.12384. Epub 2014 Feb 28.

PMID:
24581275
23.

Performance of coagulation tests in patients on therapeutic doses of rivaroxaban. A cross-sectional pharmacodynamic study based on peak and trough plasma levels.

Francart SJ, Hawes EM, Deal AM, Adcock DM, Gosselin R, Jeanneret C, Friedman KD, Moll S.

Thromb Haemost. 2014 Jun;111(6):1133-40. doi: 10.1160/TH13-10-0871. Epub 2014 Jan 9.

PMID:
24401946
24.

An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura.

Muia J, Gao W, Haberichter SL, Dolatshahi L, Zhu J, Westfield LA, Covill SC, Friedman KD, Sadler JE.

J Thromb Haemost. 2013 Aug;11(8):1511-8. doi: 10.1111/jth.12319.

25.

No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.

Flood VH, Friedman KD, Gill JC, Haberichter SL, Christopherson PA, Branchford BR, Hoffmann RG, Abshire TC, Dunn AL, Di Paola JA, Hoots WK, Brown DL, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR.

Blood. 2013 May 2;121(18):3742-4. doi: 10.1182/blood-2012-12-471672. Epub 2013 Mar 21.

26.

Collagen binding provides a sensitive screen for variant von Willebrand disease.

Flood VH, Gill JC, Friedman KD, Christopherson PA, Jacobi PM, Hoffmann RG, Montgomery RR, Haberichter SL; Zimmerman Program Investigators.

Clin Chem. 2013 Apr;59(4):684-91. doi: 10.1373/clinchem.2012.199000. Epub 2013 Jan 22.

27.

Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement.

Franzblau EB, Punzalan RC, Friedman KD, Roy A, Bilen O, Flood VH.

Pediatr Blood Cancer. 2013 Mar;60(3):500-2. doi: 10.1002/pbc.24383. Epub 2012 Nov 5.

28.

In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution.

Dumont LJ, Cancelas JA, Graminske S, Friedman KD, Vassallo RR, Whitley PH, Rugg N, Dumont DF, Herschel L, Siegal AH, Szczepiorkowski ZM, Fender L, Razatos A.

Transfusion. 2013 May;53(5):972-80. doi: 10.1111/j.1537-2995.2012.03841.x. Epub 2012 Aug 6.

PMID:
22882530
29.

Comparison of type I, type III and type VI collagen binding assays in diagnosis of von Willebrand disease.

Flood VH, Gill JC, Christopherson PA, Wren JS, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR.

J Thromb Haemost. 2012 Jul;10(7):1425-32. doi: 10.1111/j.1538-7836.2012.04747.x.

30.

Critical von Willebrand factor A1 domain residues influence type VI collagen binding.

Flood VH, Gill JC, Christopherson PA, Bellissimo DB, Friedman KD, Haberichter SL, Lentz SR, Montgomery RR.

J Thromb Haemost. 2012 Jul;10(7):1417-24. doi: 10.1111/j.1538-7836.2012.04746.x.

31.

Intersection of mechanisms of type 2A VWD through defects in VWF multimerization, secretion, ADAMTS-13 susceptibility, and regulated storage.

Jacobi PM, Gill JC, Flood VH, Jakab DA, Friedman KD, Haberichter SL.

Blood. 2012 May 10;119(19):4543-53. doi: 10.1182/blood-2011-06-360875. Epub 2012 Mar 19.

32.

Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease.

Cushing M, Kawaguchi K, Friedman KD, Mark T.

Transfusion. 2012 Jul;52(7):1535-41. doi: 10.1111/j.1537-2995.2011.03500.x. Epub 2012 Jan 9.

PMID:
22229973
33.

VWF mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.

Bellissimo DB, Christopherson PA, Flood VH, Gill JC, Friedman KD, Haberichter SL, Shapiro AD, Abshire TC, Leissinger C, Hoots WK, Lusher JM, Ragni MV, Montgomery RR.

Blood. 2012 Mar 1;119(9):2135-40. doi: 10.1182/blood-2011-10-384610. Epub 2011 Dec 23.

34.

Von Willebrand disease in the United States: a perspective from Wisconsin.

Flood VH, Gill JC, Friedman KD, Bellissimo DB, Haberichter SL, Montgomery RR.

Semin Thromb Hemost. 2011 Jul;37(5):528-34. doi: 10.1055/s-0031-1281039. Epub 2011 Nov 18. Review.

35.

Hematocrit and C-reactive protein predict treatment response times in ADAMTS13-deficient thrombotic microangiopathy.

Samia NI, Friedman KD, Gottschall JL, Raife TJ.

J Clin Apher. 2011;26(3):138-45. doi: 10.1002/jca.20284. Epub 2011 Apr 1.

PMID:
21462238
36.

Therapeutic consequences for misdiagnosis of type 2N von Willebrand disease.

Gupta M, Lillicrap D, Stain AM, Friedman KD, Carcao MD.

Pediatr Blood Cancer. 2011 Dec 1;57(6):1081-3. doi: 10.1002/pbc.23120. Epub 2011 Mar 21.

PMID:
21425451
37.

Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.

Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Hoffmann RG, Montgomery RR.

Blood. 2011 Feb 10;117(6):e67-74. doi: 10.1182/blood-2010-08-299016. Epub 2010 Dec 10.

38.

Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas.

Lee CA, Hubbard A, Sabin CA, Budde U, Castaman G, Favaloro EJ, Friedman KD, Federici AB; I5th-SSC Subcommittee on VWF.

J Thromb Haemost. 2011 Jan;9(1):220-2. doi: 10.1111/j.1538-7836.2010.04102.x. No abstract available.

39.

Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD.

Flood VH, Lederman CA, Wren JS, Christopherson PA, Friedman KD, Hoffmann RG, Montgomery RR.

J Thromb Haemost. 2010 Jun;8(6):1431-3. doi: 10.1111/j.1538-7836.2010.03869.x. Epub 2010 Mar 23. No abstract available.

40.

Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.

Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL, Branchford BR, Hoffmann RG, Abshire TC, Di Paola JA, Hoots WK, Leissinger C, Lusher JM, Ragni MV, Shapiro AD, Montgomery RR.

Blood. 2010 Jul 15;116(2):280-6. doi: 10.1182/blood-2009-10-249102. Epub 2010 Mar 15.

41.

Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function.

Flood VH, Friedman KD, Gill JC, Morateck PA, Wren JS, Scott JP, Montgomery RR.

J Thromb Haemost. 2009 Nov;7(11):1832-9. doi: 10.1111/j.1538-7836.2009.03594.x. Epub 2009 Aug 19.

42.

Elevated procalcitonin and C-reactive protein as potential biomarkers of sepsis in a subpopulation of thrombotic microangiopathy patients.

Erickson YO, Samia NI, Bedell B, Friedman KD, Atkinson BS, Raife TJ.

J Clin Apher. 2009;24(4):150-4. doi: 10.1002/jca.20205.

43.

Value of ADAMTS13 activity and inhibitor in the postmortem diagnosis of thrombotic thrombocytopenic purpura.

Dwyre DM, Dursteler B, Nashelsky M, Friedman KD, Raife TJ.

J Clin Apher. 2009;24(3):106-10. doi: 10.1002/jca.20196.

PMID:
19253359
44.

Type 2B von Willebrand disease associated with the release of platelet agglutinates from megakaryocytes in the bone marrow.

Slayton WB, Patel M, Sola-Visner M, Harris N, Rivers A, Montgomery RR, Friedman KD.

J Pediatr Hematol Oncol. 2008 Sep;30(9):708-11. doi: 10.1097/MPH.0b013e31817541cd.

45.

Comparison and stability of ADAMTS13 activity in therapeutic plasma products.

Scott EA, Puca KE, Pietz BC, Duchateau BK, Friedman KD.

Transfusion. 2007 Jan;47(1):120-5.

PMID:
17207240
46.

Urgent reversal of warfarin with prothrombin complex concentrate.

Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM.

J Thromb Haemost. 2006 May;4(5):967-70.

47.
48.

Genetic mutations in von Willebrand disease identified by DHPLC and DNA sequence analysis.

Kakela JK, Friedman KD, Haberichter SL, Buchholz NP, Christopherson PA, Kroner PA, Gill JC, Montgomery RR, Bellissimo DB.

Mol Genet Metab. 2006 Mar;87(3):262-71.

PMID:
16321553
49.

A prothrombotic phenotype in the Copenhagen rat strain.

Cooley BC, Chen CY, Friedman KD, Datta Y.

Thromb Res. 2005;115(1-2):153-7.

PMID:
15567467
50.

Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded plasmas.

Tripodi A, Chantarangkul V, Böhm M, Budde U, Dong JF, Friedman KD, Galbusera M, Girma JP, Moake J, Rick ME, Studt JD, Turecek PL, Mannucci PM.

J Thromb Haemost. 2004 Sep;2(9):1601-9.

Supplemental Content

Loading ...
Support Center